Tenax Therapeutics Inc.
- Address
- 101 Glen Lennox Drive Suite 300
Sponsor Overview
Specializations
Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction
Tenax Therapeutics Inc. focuses on pulmonary hypertension in the setting of heart failure with preserved left ventricular ejection fraction, addressing a cardiopulmonary condition marked by impaired exercise capacity and elevated pulmonary pressures.
- PH-HFpEF
- Exercise Limitation
- 6-Minute Walk Distance
The clinical program centers on improving functional status and evaluating treatment effects in patients with this overlapping cardiac and pulmonary vascular disorder.
Cardiopulmonary Symptom Management
The sponsor’s research interest includes symptoms and functional impairment associated with pulmonary vascular disease and heart failure, with attention to patient mobility and daily physical performance.
- Functional Capacity
- Dyspnea
- Exercise Tolerance
Its funded activity reflects a therapeutic focus on measurable improvements in activity limitation within a mixed cardiovascular and respiratory disease population.
Oral Inotropic and Vasodilator Therapy
Tenax Therapeutics Inc. is engaged in research on levosimendan, a therapy of interest in cardiopulmonary disease management, with emphasis on treatment options for patients who remain limited by PH-HFpEF.
- Levosimendan
- Oral Therapy
- Hemodynamic Support
The sponsor’s work highlights pharmacologic strategies aimed at improving exertional performance in a complex heart-lung condition.
Clinical Evaluation in Multinational Sites
The company’s trial activity spans multiple collaborating research sites across several countries, supporting clinical investigation in a geographically broad pulmonary hypertension population.
- Multinational Enrollment
- Site Collaboration
- Patient Recruitment
This research footprint is aligned with the assessment of therapies for a specialized cardiovascular indication requiring coordinated clinical access.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 3, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Levosimendan in Patients with Pulmonary Hypertension and HFpEF |  Austria Bulgaria Czechia France Germany Hungary Italy Poland Spain | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 57 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases1 trial359 other sponsors
Partnered Research Centres
57 centres- Address
- Ul. Rudolfa Weigla 5, 53-114 Wroclaw
- Address
- Ringstraße 60, 5280 Braunau am Inn
- Address
- Via Consolare Valeria N 1, 98124 Messina
- Address
- Piazza Oms 1, 24127 Bergamo
- Address
- Warener Strasse 7, Biesdorf, 12683 Berlin
- Address
- Langenbeckstrasse 1, Oberstadt, 55131 Mainz
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Tenax Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.